Synergistic activity of magnolol with azoles and its possible antifungal mechanism against Candida albicans

Journal of Applied Microbiology

Volumn 118, Issue 4, 2015, Pages 826-838

  Sun, L M ^a   Liao, K ^a   Liang, S ^a   Yu, P H ^a   Wang, D Y ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

ATP binding cassette transporter; Candida albicans; Efflux inhibition; Ergosterol; Fluconazole; Magnolol

Indexed keywords

ALCOHOLS; BIOCHEMISTRY; BIOSYNTHESIS; CANDIDA; DRUG THERAPY; POLYMERASE CHAIN REACTION; TRANSCRIPTION; YEAST;

ANTIFUNGALS; ATP BINDING CASSETTE TRANSPORTERS; CANDIDA ALBICANS; EFFLUX INHIBITION; ERGOSTEROL; FLUCONAZOLE; MAGNOLOL; MULTIDRUG RESISTANCE; RHODAMINE 123; SYNERGIC EFFECTS;

SUBSTRATES;

ABC TRANSPORTER; ABC TRANSPORTER CDR1P; ERGOSTEROL; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MAGNOLOL; MICONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE; ANTIFUNGAL AGENT; BIPHENYL DERIVATIVE; CARRIER PROTEIN; FUNGAL PROTEIN; LIGNAN; PYRROLE DERIVATIVE;

ALCOHOL; ANTIMICROBIAL ACTIVITY; CELL ORGANELLE; FUNGUS; INHIBITOR; MUTATION; POLYMERASE CHAIN REACTION; SUBSTRATE; TOLERANCE;

AGAR DIFFUSION; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; BROTH DILUTION; CANDIDA ALBICANS; CONTROLLED STUDY; DELETION MUTANT; DRUG MECHANISM; DRUG POTENTIATION; FUNGUS GROWTH; GENE OVEREXPRESSION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; METABOLISM;

CANDIDA; CANDIDA ALBICANS;

ANTIFUNGAL AGENTS; AZOLES; BIPHENYL COMPOUNDS; CANDIDA ALBICANS; DRUG SYNERGISM; ERGOSTEROL; FLUCONAZOLE; FUNGAL PROTEINS; LIGNANS; MEMBRANE TRANSPORT PROTEINS; UP-REGULATION;

EID: 84924769593     PISSN: 13645072     EISSN: 13652672     Source Type: Journal    
DOI: 10.1111/jam.12737     Document Type: Article

References (42)

1. Bang, K.H., Kim, Y.K., Min, B.S., Na, M.K., Rhee, Y.H., Lee, J.P. and Bae, K.H. (2000) Antifungal activity of magnolol and honokiol. Arch Pharm Res 23, 46-49.
2. Barchiesi, F., Falconi, D.F.L. and Scalise, G. (1997) In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. Antimicrob Agents Chemother 41, 1812-1814.
3. Bondaryk, M., Kurzatkowski, W. and Staniszewska, M. (2013) Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development. Postepy Dermatol Alergol 30, 293-301.
4. Calabrese, D., Bille, J. and Sanglard, D. (2000) A novel multidrug efflux transporter gene of the major facilitator superfamily from Candida albicans (FLU1) conferring resistance to fluconazole. Microbiology 146, 2743-2754.
5. Chen, C.R., Tan, R., Qu, W.M., Wu, Z., Wang, Y., Urade, Y. and Huang, Z.L. (2011) Magnolol, a major bioactive constituent of the bark of Magnolia officinalis, exerts antiepileptic effects via the GABA/benzodiazepine receptor complex in mice. Br J Pharmacol 164, 1534-1546.
6. Chen, M.C., Lee, C.F., Huang, W.H. and Chou, T.C. (2013) Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1alpha/VEGF signaling pathway in human bladder cancer cells. Biochem Pharmacol 85, 1278-1287.
7. Chuang, T.C., Hsu, S.C., Cheng, Y.T., Shao, W.S., Wu, K., Fang, G.S., Ou, C.C. and Wang, V. (2011) Magnolol down-regulates HER2 gene expression, leading to inhibition of HER2-mediated metastatic potential in ovarian cancer cells. Cancer Lett 311, 11-19.
8. Clinical and Laboratory Standards Institute (CLSI). (2008) M27-A3, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard, 3rd edn. Wayne, PA: Clinical and Laboratory Standards Institute.
9. Faria-Ramos, I., Farinha, S., Neves-Maia, J., Tavares, P.R., Miranda, I.M., Estevinho, L.M., Pina-Vaz, C. and Rodrigues, A.G. (2014) Development of cross-resistance by Aspergillus fumigatus to clinical azoles following exposure to prochloraz, an agricultural azole. BMC Microbiol 14, 155.
10. Fonzi, W.A. and Irwin, M.Y. (1993) Isogenic strain construction and gene mapping in Candida albicans. Genetics 134, 717-728.
11. Forastiero, A., Mesa-Arango, A.C., Alastruey-Izquierdo, A., Alcazar-Fuoli, L., Bernal-Martinez, L., Pelaez, T., Lopez, J.F., Grimalt, J.O. et al. (2013) Candida tropicalis antifungal cross-resistance is related to different azole target (Erg11p) modifications. Antimicrob Agents Chemother 57, 4769-4781.
12. Forster, S., Thumser, A.E., Hood, S.R. and Plant, N. (2012) Characterization of rhodamine-123 as a tracer dye for use in vitro drug transport assays. PLoS One 7, e33253.
13. Galgiani, J.N. (1993) Susceptibility testing of fungi: current status of the standardization process. Antimicrob Agents Chemother 37, 2517-2521.
14. Henry, K.W., Nickels, J.T. and Edlind, T.D. (2000) Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrob Agents Chemother 44, 2693-2700.
15. Jiang, C., Dong, D., Yu, B., Cai, G., Wang, X., Ji, Y. and Peng, Y. (2013) Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China. J Antimicrob Chemother 68, 778-785.
16. Jin, J., Guo, N., Zhang, J., Ding, Y., Tang, X., Liang, J., Li, L., Deng, X. et al. (2010) The synergy of honokiol and fluconazole against clinical isolates of azole-resistant Candida albicans. Lett Appl Microbiol 51, 351-357.
17. Johnson, M.D. and Perfect, J.R. (2010) Use of antifungal combination therapy: agents, order, and timing. Curr Fungal Infect Rep 4, 87-95.
18. Johnston, P.A. and Coddington, A. (1984) Drug resistance in the fission yeast Schizosaccharomyces pombe: pleiotropic mutations affecting the oleic acid and sterol composition of cell membranes. Curr Genet 8, 37-43.
19. Lamping, E., Ranchod, A., Nakamura, K., Tyndall, J.D., Niimi, K., Holmes, A.R., Niimi, M. and Cannon, R.D. (2009) Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei. Antimicrob Agents Chemother 53, 354-369.
20. Larsen, B., Anderson, S., Brockman, A., Essmann, M. and Schmidt, M. (2006) Key physiological differences in Candida albicans CDR1 induction by steroid hormones and antifungal drugs. Yeast 23, 795-802.
21. Lehan, P.H., Furcolow, M.L., Brasher, C.A. and Larsh, H.W. (1956) Therapeutic trials with the newer antifungal agents. Antibiot Annu, 467-469.
22. Linares, C.E., Giacomelli, S.R., Altenhofen, D., Alves, S.H., Morsch, V.M. and Schetinger, M.R. (2013) Fluconazole and amphotericin-B resistance are associated with increased catalase and superoxide dismutase activity in Candida albicans and Candida dubliniensis. Rev Soc Bras Med Trop 46, 752-758.
23. Lingegowda, P.B., Tan, C.K., Tan, A.L. and Tan, B.H. (2011) Selection of resistant fungi in liver transplant recipients during use of newer antifungal agents - a report of two cases. Ann Acad Med Singapore 40, 287-290.
24. Marchetti, O., Moreillon, P., Entenza, J.M., Vouillamoz, J., Glauser, M.P., Bille, J. and Sanglard, D. (2003) Fungicidal synergism of fluconazole and cyclosporine in Candida albicans is not dependent on multidrug efflux transporters encoded by the CDR1, CDR2, CaMDR1, and FLU1 genes. Antimicrob Agents Chemother 47, 1565-1570.
25. Mukherjee, P.K., Chandra, J., Kuhn, D.M. and Ghannoum, M.A. (2003) Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun 71, 4333-4340.
26. Nabikhan, A., Kandasamy, K., Raj, A. and Alikunhi, N.M. (2010) Synthesis of antimicrobial silver nanoparticles by callus and leaf extracts from saltmarsh plant, Sesuvium portulacastrum L. Colloids Surf B Biointerfaces 79, 488-493.
27. Odds, F.C. (2003) Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52, 1.
28. Otzen, T., Wempe, E.G., Kunz, B., Bartels, R., Lehwark-Yvetot, G., Hansel, W., Schaper, K.J. and Seydel, J.K. (2004) Folate-synthesizing enzyme system as target for development of inhibitors and inhibitor combinations against Candida albicans-synthesis and biological activity of new 2, 4-diaminopyrimidines and 4′-substituted 4-aminodiphenyl sulfones. J Med Chem 47, 240-253.
29. Pasrija, R., Panwar, S.L. and Prasad, R. (2008) Multidrug transporters CaCdr1p and CaMdr1p of Candida albicans display different lipid specificities: both ergosterol and sphingolipids are essential for targeting of CaCdr1p to membrane rafts. Antimicrob Agents Chemother 52, 694-704.
30. Perea, S., Gonzalez, G., Fothergill, A.W., Sutton, D.A. and Rinaldi, M.G. (2002) In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles. J Clin Microbiol 40, 1831-1833.
31. Ren, B., Dai, H.Q., Pei, G., Tong, Y.J., Zhuo, Y., Yang, N., Su, M.Y., Huang, P. et al. (2014) ABC transporters coupled with the elevated ergosterol contents contribute to the azole resistance and amphotericin B susceptibility. Appl Microbiol Biotechnol 98, 2609-2616.
32. Rognon, B., Kozovska, Z., Coste, A.T., Pardini, G. and Sanglard, D. (2006) Identification of promoter elements responsible for the regulation of MDR1 from Candida albicans, a major facilitator transporter involved in azole resistance. Microbiology 152, 3701-3722.
33. Sanglard, D., Ischer, F., Monod, M. and Bille, J. (1996) Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother 40, 2300-2305.
34. Sanglard, D., Ischer, F., Monod, M. and Bille, J. (1997) Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143, 405-416.
35. Sardi, J.C., Scorzoni, L., Bernardi, T., Fusco-Almeida, A.M. and Mendes, G.M. (2013) Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol 62, 10-24.
36. Spampinato, C. and Leonardi, D. (2013) Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. Biomed Res Int 2013, 204237.
37. Sun, L., Sun, S., Cheng, A., Wu, X., Zhang, Y. and Lou, H. (2009) In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans. Antimicrob Agents Chemother 53, 1586-1591.
38. Sun, L.M., Cheng, A.X., Wu, X.Z., Zhang, H.J. and Lou, H.X. (2010) Synergistic mechanisms of retigeric acid B and azoles against Candida albicans. J Appl Microbiol 108, 341-348.
39. Vale-Silva, L.A., Coste, A.T., Ischer, F., Parker, J.E., Kelly, S.L., Pinto, E. and Sanglard, D. (2012) Azole resistance by loss of function of the sterol Delta(5), (6)-desaturase gene (ERG3) in Candida albicans does not necessarily decrease virulence. Antimicrob Agents Chemother 56, 1960-1968.
40. White, T.C. (1997) Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 41, 1482-1487.
41. Xiang, M.J., Liu, J.Y., Ni, P.H., Wang, S., Shi, C., Wei, B., Ni, Y.X. and Ge, H.L. (2013) Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans. FEMS Yeast Res 13, 386-393.
42. Zhao, Y., Stensvold, C.R., Perlin, D.S. and Arendrup, M.C. (2013) Azole resistance in Aspergillus fumigatus from bronchoalveolar lavage fluid samples of patients with chronic diseases. J Antimicrob Chemother 68, 1497-1504.